Learn more about our programs
Urothelial Cancer

Are There Treatment Options for Advanced Urothelial Cancer?

Live on Friday, January 28, 2022
at 1:00 PM EST

Register Now

Produced in collaboration with Bladder Cancer Advocacy Network (BCAN)
Support for this patient education program was provided by an educational grant from Gilead Sciences, Inc.

If you or a loved one has been diagnosed with bladder (urothelial) cancer, it can be overwhelming, especially if the cancer has spread to other areas of the body. Effective management of urothelial cancer involves fostering open lines of communication with the health care team, including sharing your expectations for treatment and insights on potential side effects that could impact your daily life.

Join an expert panel featuring an oncologist, a patient with bladder cancer, and a patient advocate, as they share information to help you make informed decisions about your treatment and describe ways to recognize and discuss side effects with your care team. Panelists will also share available support options to help maintain a healthy lifestyle despite a urothelial-cancer diagnosis.

The expert panel will discuss:

  • How your team identifies disease progression
  • Available treatments for advanced urothelial cancer
  • Differentiators of treatment
  • Expected side effects and appropriate management
  • Management of anxiety of recurrence
  • Support organizations and resources for patients and caregivers

The live program will include a Q&A session, and you can send your questions to the expert panel now:

Register now to watch the program live or on-demand later.

 

Speakers

Elizabeth Plimack, MD, MS

Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Fox Chase Cancer Center

Stephanie Chisolm, PhD

Director of Education & Advocacy, Bladder Cancer Advocacy Network

Mark Lannutti

Patient Speaker

Mark Lannutti’s bladder cancer diagnosis came in 2014, and the cancer was treated until treatment stopped working. Thus, Mark had a cystoprostatectomy with a neobladder diversion with no complications until 2018, when the cancer had metastasized to the right kidney and adrenal gland. His oncologist chose to do MVAC chemotherapy, which worked until 2020 when the cancer had moved on to the liver. Pembrolizumab was tried with no success, so enfortumab vedotin was offered. Mark has been treated with enfortumab vedotin since 2020, but he’ll be starting SRBT radiation treatment in December. Depending on the progression of the neuropathy, Mark might undergo a carboplatin-gemcitabine treatment. Mark’s extensive medical history enables him to speak on treatment options for advanced bladder cancer.

John R. Lanci, PhD

Interview Participant, Patient

Karl

Interview Participant, Patient

 

Partners

  • BCAN logo